Investigators sought to quantify whether continuing low-dose aspirin through the perioperative period altered operative metrics for patients undergoing minimally invasive anterior-to-psoas (MIS-ATP) lumbar fusion. The study was retrospective and used a propensity-matched design. Operative time, estimated blood loss (EBL), postoperative day‑1 hemoglobin, and length of stay were reported as primary outcomes. After matching, the cohort comprised 86 pairs (n=172).
Operative time did not differ meaningfully between groups: 224.7±97.9 minutes for continuers versus 228.6±90.1 minutes for discontinuers (P =0.79). The investigators reported mean EBL of 244.4±456.0 mL with continuation and 278.4±418.7 mL with discontinuation (P =0.62). Postoperative day‑1 hemoglobin averaged 10.88±1.49 g/dL in continuers and 11.08±1.76 g/dL in discontinuers (P =0.41). Length of stay showed no statistically significant difference (4.83±3.72 vs . 4.20±2.49 days; P =0.22). These reported metrics indicate no signal of increased intraoperative bleeding or prolonged hospitalization attributable to continued antiplatelet therapy in this matched sample.
The source did not report specific aspirin dosing regimens beyond describing use of “low‑dose aspirin,” nor did it provide detailed intraoperative hemostasis protocols. The study team described results in aggregate form only; individual patient-level hemostatic management details were not supplied in the abstract.
The study team included transfusion and retroperitoneal hematoma as important safety endpoints. Transfusion occurred in 18.6% of aspirin continuers versus 15.1% of those who discontinued (P =0.54). Retroperitoneal hematoma was reported in 1.2% of patients in both groups (P =1.00). No statistically significant differences were identified for these events in the propensity-matched cohort.
These outcome data come directly from the abstract and reflect perioperative morbidity measures rather than longer-term thrombotic or cardiovascular outcomes. The authors did not report additional bleeding complications, reoperation for bleeding, or granular transfusion triggers in the abstract, so those specifics cannot be inferred beyond the supplied numbers.
The investigators identified 455 eligible patients who underwent MIS-ATP fusion with supplemental posterior percutaneous fixation between 2014 and 2020 at a single academic medical center. Of those, 134 (29.5%) continued aspirin through the perioperative period and 321 (70.5%) discontinued preoperatively. Propensity score matching used a 1:1 nearest‑neighbor algorithm and incorporated age, sex, BMI, race/ethnicity, number of fusion levels, comorbidities (hypertension, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease, chronic kidney disease), smoking status, alcohol use, and preoperative laboratory values.
Matching produced 86 well-balanced pairs (n=172) for the primary analysis. The abstract does not list baseline numerics for each covariate after matching beyond stating the pairs were “well-balanced”; specific standardized mean differences, caliper widths, or matching diagnostics were not reported in the abstract text. Readers should interpret the matching claims with that reporting limitation in mind.
The study team performed a subanalysis that compared aspirin continuers to patients who held aspirin for at least seven days preoperatively. That subanalysis included 15 matched pairs. The authors reported no outcome advantage to holding aspirin for ≥7 days prior to surgery relative to continuation. The abstract provides no further stratified statistics for this subgroup beyond the statement that no benefit was observed.
The limited size of the seven-day-hold subgroup (15 pairs) was reported in the abstract and constrains interpretation of those particular findings. The source did not provide power calculations specific to this subanalysis in the abstract.
The investigators described a single‑center, retrospective cohort using propensity matching; the abstract explicitly reports the study design. The source did not provide randomized allocation, blinding, or detailed aspirin dosing schedules in the abstract. The sample frame spanned 2014–2020; any temporal practice changes within that interval are not detailed in the abstract.
The reported outcomes focus on perioperative bleeding metrics and immediate complications. The abstract did not report long-term thrombotic events or cardiovascular outcomes after aspirin continuation versus discontinuation, and it did not specify criteria used to define which patients were considered “appropriately selected” for continuation. The authors declared no conflicts of interest in the source document.
Taken together, the propensity-matched data presented in the abstract indicate that perioperative continuation of low-dose aspirin in selected patients undergoing MIS-ATP lumbar fusion was not associated with increased measured surgical morbidity or immediate postoperative complications at this single academic center. The design and reporting limitations described above—single-center, retrospective design, lack of dosing and detailed selection criteria, small subgroup sizes—remain unresolved by the abstract and warrant cautious interpretation. Further prospective, multicenter data with transparent reporting of aspirin regimens, matching diagnostics, and longer-term cardiovascular outcomes would be needed to answer the open clinical questions left by this report.